1 results match your criteria: "Enterin Research Institute and Enterin[Affiliation]"
Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial.
Ann Intern Med
December 2022
Enterin Research Institute and Enterin, Inc., Philadelphia, Pennsylvania (D.B.).
Background: Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhibits the formation of αS aggregates and improved constipation in an open-label study in patients with PD.
Objective: To evaluate the safety and efficacy of oral ENT-01 for constipation and neurologic symptoms in patients with PD and constipation.